brodalumab   Click here for help

GtoPdb Ligand ID: 7540

Synonyms: AMG-827 | AMG827 | Kyntheum® | Lumicef® | Siliq®
Approved drug Immunopharmacology Ligand
brodalumab is an approved drug (Japan (2016), FDA (2017), EMA (2017))
Compound class: Antibody
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Brodalumab was first approved in Japan (2016), and by the US FDA for plaque psoriasis the following year. Regulatory decisions are pending elsewhere. Clinical trials for the treatment of psoriatic arthritis (Phase 2I), moderate to severe plaque psoriasis (Phase 2I) and asthma (Phase 2) are ongoing. Encouraging results from a Phase 2 study have been reported [4].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The IL-17 pathway is an established driver of psoriasis pathogenesis [1-3]. Brodalumab is an anti-IL17RA monoclonal antibody. Competitive inhibition of IL-17RA by brodalumab in psoriatic skin leads to rapid dose-dependent transcriptomal normalisation, ie genes up-regulated in psoraisis are returned to normal levels of transcription. This is accompanied by decreased keratinocyte hyperplasia and leukocyte infiltration, which are effects indicating a positive clinical response [6].